Blood-pressure-lowering peptide (ISHIYVWK)
A small peptide that blocks ACE, an enzyme that raises blood pressure; studied as a possible treatment for high blood pressure, but still experimental and not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Literature-extracted sequence peptide — synthesized for bioassay as documented in linked reference(s)
Fork this card to add platform evidence →
Activity measured in linked reference(s) — IC50/MIC/cytotoxicity data
Fork this card to add platform evidence →
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could a simple chemical modification protect a natural peptide from being broken down in the gut before it does any good?
Many natural peptides that lower blood pressure never make it past the digestive tract in one piece. If this modification works, it could be a cheap, manufacturable way to turn a food-derived ingredient into a reliable functional food or supplement for people managing mild hypertension.
Could this peptide do double duty, lowering blood pressure AND helping the heart handle fluid and stress better?
Drugs that block both of these pathways at once have shown stronger results in heart failure patients than single-target drugs alone. If this peptide turns out to share that mechanism, it could open a path toward a natural ingredient with broader cardiovascular benefit, not just blood pressure control.
Does one specific chemical feature of this peptide matter more than the rest for how well it works?
If a single hydroxyl group on one amino acid turns out to be critical, researchers could design stronger versions more precisely, instead of guessing. That kind of roadmap could speed up development of better food-derived ingredients for blood pressure management.
Could this peptide target only the enzyme that raises blood pressure while leaving alone the one that protects the heart?
Some blood pressure compounds inadvertently hit a closely related enzyme that actually shields the heart from damage. If this peptide turns out to be selective, it would be a meaningfully safer profile than non-selective inhibitors, which matters most for people with existing heart conditions.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8795640468597412 | boltz-2 |
| ranking score | 0.8180637359619141 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | colabfold_nvidia |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-25 |
▸citationbibtex
@peptide{pep04717,
sequence = {ISHIYVWK},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}